Loading
A phase 1/2 trial of gemcitabine, nab-paclitaxel, erlotinib, nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) and other drugs in pancreatic cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel is a phase 1/2, interventional study registered as NCT06483555 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 104 participants, started 2025-02-06 and due to reach its primary completion in 2027-08. Interventions recorded: Gemcitabine; Nab paclitaxel; Erlotinib; NALIRIFOX; Folfirinox. Conditions listed: Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm. Primary outcome: Adverse Events per Common Terminology Criteria for Adverse Events (NCI-CTCAE); Dose-limiting toxicity (DLT); Overall survival- classical metastatic pancreatic adenocarcinoma. Pancreatic eligibility wording from the registry: "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 Histological or cytological evidence/confirmation of unresectable, borderline resectable, or metastatic (basal-like and classical) pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Nab-paclitaxel, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Locally advanced unresectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.